Exploring Acute Pancreatitis After Orlistat Use: A Case Report
Year: 2025
Type: article
Study design: Case Report
Abstract: Orlistat is an FDA-approved medication for obesity management that functions as a pancreatic lipase inhibitor. This medication is accessible without a prescription in numerous developed nations. As its utilization rises, the likelihood of experiencing adverse events also increases. A thorough understanding of these events is crucial for making informed decisions and ensuring effective management. We describe the case of a 23-year-old female who presented with acute pancreatitis after she started orlistat. We reviewed the association between orlistat use and acute pancreatitis, analyzing clinical cases and potential risk factors. By examining available medical literature and case studies, our study aims to provide insights into the correlation between orlistat therapy and the manifestation of acute pancreatitis.
Source: Cureus
DOI: 10.7759/cureus.80832
Authors: Abeer Qasim, Abhilasha Jyala, Ornela Thartori, Haider Ghazanfar, Sarah Moore, Elona Shehi
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4408613265